HYNR-CS-Allo is under clinical development by Corestemchemon and currently in Phase I for Cerebellar Ataxia. According to GlobalData, Phase I drugs for Cerebellar Ataxia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HYNR-CS-Allo LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HYNR-CS-Allo overview
HYNR-CS-Allo (HLA-haplo matched allogenic bone marrow derived stem cells) is under development for the treatment of cerebellar ataxia, multiple system atrophy, spinocerebellar ataxia and amyotrophic lateral sclerosis (ALS). It administered intrathecally as suspension. This therapy comprises of allogenic bone marrow derived mesenchymal stem cells.
Corestemchemon overview
Corestemchemon is a biotechnology company that researches and commercializes stem cell technology. It develops stem cell therapy for the treatment of incurable diseases. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of Lou Gehrig’s disease. The company’s other pipeline products include CS20AT04 (Lupus), CS10BR05 (MSA), which are at the stage of phase I clinical trial. Corestemchemon is involved in research and development activities in the field of stem cell therapy. The company also develops various therapy products for the treatment of lupus, multiple system atrophy, osteoarthritis, and other diseases. Corestemchemon is headquartered in Seongnam-si, Gyeonggi-do, South Korea.
For a complete picture of HYNR-CS-Allo’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
